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Edited by Lukas HuberAbstract Annexin A2 is a multifunctional protein and its cellu-
lar functions are regulated by post-translational modiﬁcations
and ligand binding. When puriﬁed from porcine intestinal muco-
sa and transformed mouse Krebs II cells, SDS–PAGE revealed
high-molecular-mass forms in addition to the 36 kDa protomer.
These forms were identiﬁed as poly-/multi-ubiquitin conjugates
of annexin A2, and ubiquitination represents a novel post-trans-
lational modiﬁcation of this protein. Subcellular fractionation of
mouse Krebs II cells revealed an enrichment of annexin A2-ubi-
quitin conjugates in the Triton X-100 resistant cytoskeleton frac-
tion, suggesting that ubiquitinated annexin A2 may have a role
associated with its function as an actin-binding protein.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Post-translational modiﬁcation1. Introduction
Annexin A2 (anxA2) is a multifunctional Ca2+-, lipid-, and
actin-binding protein implicated in a number of intracellular
functions such as signal transduction, membrane traﬃcking
and mRNA transport [1,2], as well as the regulation of mem-
brane/cytoskeleton contacts and extracellular functions [1,3].
The anxA2 protomer is cleaved by chymotrypsin into a 33
kDa C-terminal core domain, and a 3 kDa N-terminal do-
main which consists of 30 amino acids of which the ﬁrst 14
residues constitute the binding site for its S100 protein bind-
ing partner, p11 [4]. Each of the two functional domains
can be modiﬁed post-translationally in vivo and the modiﬁca-
tions aﬀect its binding of diﬀerent ligands and thus its cellular
functions. Acetylation at Ser1 is necessary for its binding of
p11 [5], while proteolytic removal of the N-terminal domain
abolishes binding to lipid rafts in smooth muscle [6]. Further-
more, anxA2 can be phosphorylated on Tyr23 [7], Ser11 andAbbreviations: anxA2, annexin A2; CUE, coupling of ubiquitin con-
jugation to ER degradation; ECL, enhanced chemiluminescence;
HRP, horseradish peroxidase; Ub, ubiquitin; UBA, ubiquitin-asso-
ciated; UIM, ubiquitin-interacting motif
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doi:10.1016/j.febslet.2004.11.076Ser25 (the primary phosphorylation site) [8,9]. It is S-glutathi-
olated on Cys8 in vivo [10], and in addition on Cys132 in
vitro, which can be reversed by glutaredoxin [11]. These
post-translational modiﬁcations aﬀect the binding of phos-
pholipids and F-actin [1,3,12]. The C-terminal core domain
comprises the intracellular binding sites for Ca2+, phospholip-
ids and F-actin [1,12]. Calcium plays a major role in regulat-
ing the association of anxA2 with membranes and the
cytoskeleton [1,3,13].
A novel post-translational modiﬁcation of anxA2 is re-
ported in the present study. Evidence is presented that
high-molecular-mass forms of anxA2, as puriﬁed from por-
cine intestinal mucosa and mouse Krebs II cells, represent
ubiquitin (Ub) conjugates which are enriched in a Triton
X-100 insoluble particulate fraction, the cytoskeleton fraction
[14,15].2. Materials and methods
2.1. Puriﬁcation of anxA2 from porcine intestinal mucosa and Krebs II
cells
The heterotetrameric anxA22p112 complex was puriﬁed from por-
cine intestinal mucosa as described by Gerke and Weber [13], with
minor modiﬁcations. No inhibitors of Ub-conjugating enzymes and
Ub-isopeptidases were added during the procedure. Brieﬂy, the Triton
X-100 insoluble particulate fraction from porcine intestinal mucosa,
obtained in the presence of 2 mM Ca2+, was thoroughly washed before
the release of anxA2 from membranes and the cytoskeleton by 15 mM
EGTA in a deﬁned buﬀered solution with protease inhibitors and 200
mM NaCl [13] (or as indicated in the ﬁgure legend). After high-speed
centrifugation (100000 · g, 60 min at 4 C) of this EGTA extract, the
supernatant was dialysed against buﬀer A containing 10 mM imidaz-
ole–HCl (pH 7.5) and 0.5 mM DTT before a second high-speed centri-
fugation (100000 · g, 60 min at 4 C). The dialysed supernatant was
applied on a Whatmann DE52 column equilibrated with buﬀer A
and the ﬂow-through was subsequently applied on and eluted from a
Whatmann CM52 column. Further puriﬁcation was performed as de-
scribed [13]. Subcellular fractionation of mouse Krebs II cells was per-
formed essentially as described [2,15]. AnxA2 present in the
cytoskeleton fraction [15] was released from the Triton X-100 insoluble
material by a buﬀer containing 10 mM triethanolamine (pH 7.4), 250
mM sucrose, 10 mM EGTA, 130 mM KCl, and 2 mM MgCl2. It
was recovered in the supernatant after centrifugation (100000 · g, 60
min at 4 C). The salt concentration was subsequently lowered to 65
mM KCl by a 1:1 dilution with the same buﬀer without KCl and
EGTA before application on the Whatmann DE52 column. AnxA2
present in the ﬂow-through fraction was further puriﬁed as described
for porcine anxA2 [13].2.2. Immunoisolation
Rabbit anti-mouse IgG (5 lg/ml) was bound to Protein A–Sepha-
rose CL-4B beads (Amersham Pharmacia Biotech) in NET buﬀer (10
mM Tris–HCl (pH 7.4), 150 mM KCl, and 1% (w/v) Triton X-100)blished by Elsevier B.V. All rights reserved.
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three times in NET buﬀer by sedimentation (1200 g, 15 s) and further
incubated with monoclonal antibodies (5 lg/ml) directed against Ub or
anxA2 for 2 h at 4 C. After three washes with NET buﬀer, 30 lg of
puriﬁed anxA2 was added and incubated overnight at 4 C. The Pro-
tein A–Sepharose beads with bound Ub or anxA2 antibodies were sed-
imented (1200 g, 15 s) and washed several times with NET buﬀer. The
beads were ﬁnally resuspended in SDS sample buﬀer, heated for 3 min
at 95 C and the desorbed proteins were resolved by SDS–PAGE [16]
and immunoblotted with either monoclonal anxA2 or Ub antibodies.
2.3. SDS–PAGE and Western blot analysis
SDS–PAGE was performed [16] in 10% (w/v) gels and the proteins
were transferred onto 0.2 lm nitrocellulose membrane (Schleicher
and Schu¨ell) by overnight blotting performed at 120 V h [17]. AnxA2
and Ub were detected using monoclonal antibodies directed against
anxA2 (Transduction Lab.) and Ub (Zymed), respectively, followed
by anti-mouse horseradish peroxidase (HRP)-labelled secondary anti-
bodies (BioRad). Binding was visualised using the enhanced chemilu-
minescence (ECL) method and ECL ﬁlms.
2.4. Protein determination
Protein was measured by the Bradford dye-binding assay [18] using
BSA as standard.3. Results and discussion
3.1. High-molecular-mass forms of anxA2 in porcine intestinal
mucosa
It was observed during puriﬁcation of anxA2 from porcine
intestinal mucosa that when 200 mM NaCl was used instead
of 600 mM [13] during the preparation of the Triton X-100
insoluble particulate fraction and the subsequent EGTA ex-
tract (see Section 2), then several high-molecular-mass forms
of anxA2 were identiﬁed by Western blot analyses using mono-
clonal anxA2 antibodies (Fig. 1C, lanes 2–3). On passage of
the dialysed EGTA extract (100000 · g supernatant) through
a DE52 column, most of the anxA2 high-molecular-mass
forms were retained on the column, whereas the 36 kDa form
passed through (Fig. 1D, lanes 5–6). However, using a low
concentration of NaCl (25 mM) resulted in an almost completeFig. 1. High-molecular-mass forms of annexin A2. Dialysed EGTA extracts o
mucosa were obtained using three diﬀerent concentrations of NaCl in the ext
(lanes 2 and 5) and 600 mM (lanes 3 and 6). 40 lg of protein present in the 10
and the corresponding ﬂow-through from the DE52 column (B and D) was su
B) or Western blot analysis (C and D). The membrane was probed with
secondary antibodies. Antibody binding was detected using the ECL meth
markers (St) are indicated.retention of anxA2 on the DE52 column (Fig. 1C and D, lanes
1 and 4) while the highest recovery of the 36 kDa form, with
only trace amounts of high-molecular-mass forms (Fig. 1B,
lane 6), was obtained in the presence of 600 mM NaCl. At this
point, it should be noted that overexposure of Western blots
reveals high-molecular-mass forms of anxA2 in all fractions
(result not shown). However, it is clear that a salt concentra-
tion of 200 mM KCl promotes the release of these anxA2
forms as compared to 25 and 600 mM KCl and that they
are largely retained on the DE52 column.
3.2. AnxA2 is enriched in the cytoskeleton fraction of mouse
Krebs II cells
AnxA2 is enriched in the cytoskeleton fraction (Triton X-
100 insoluble fraction) derived from Krebs II cells from which
it is released (Fig. 2A and B, lane 2) by increasing the salt con-
centration to 130 mMKCl and the temperature to 20 C [2,15].
In addition, 10 mM EGTA was added to promote the release
of anxA2 associated with phospholipids in membranes and the
cytoskeleton in a Ca2+-dependent manner. Further puriﬁca-
tion of anxA2 derived from the cytoskeleton fraction by ion-
exchange chromatography (Fig. 2B, lanes 3–5) revealed that
several high-molecular-mass forms (80–125 kDa) were ad-
sorbed to the DE52 column (Fig. 2B, lane 5), as seen for
anxA2 isolated from porcine intestinal mucosa (Fig. 1), while
two anxA2 positive bands of 50–55 kDa were only partly re-
tained on the DE52 column (Fig. 2B, lane 5). Some of the
high-molecular-mass forms of anxA2 were recovered in the
pellet on centrifugation (100000 · g) of the EGTA extract
(Fig. 2, lane 4).3.3. The high-molecular-mass forms of anxA2 represent Ub
conjugates
Ubiquitination of anxA2 was suspected, since the high-
molecular-mass anxA2 positive bands appeared as a ladder.
To verify that these forms of anxA2 puriﬁed from porcine
intestinal mucosa (Fig. 3A, lane 1) or the transformed mouse
Krebs II cells (Fig. 3A, lane 2) represent Ub conjugates, thef the Triton X-100 insoluble particulate fraction from porcine intestinal
raction procedure (see Section 2), i.e., 25 mM (lanes 1 and 4), 200 mM
0000 · g supernatant before application to the DE52 column (A and C)
bjected to 10% (w/v) SDS–PAGE and Coomassie brilliant blue (A and
monoclonal anxA2 antibodies and HRP-conjugated goat anti-mouse
od. AnxA2 standard (lane 7) and selected prestained molecular mass
Fig. 2. Enrichment of annexin A2 and its high-molecular-mass forms in the cytoskeleton fraction of Krebs II cells. Subcellular fractionation of
mouse Krebs II cells was performed as described in Section 2. 20 lg of total protein in the cytosolic and cytoskeleton fractions was subjected to 10%
(w/v) SDS–PAGE and Coomassie brilliant blue (A) or Western blot (B) analysis with monoclonal anxA2 antibodies and HRP-conjugated goat anti-
mouse secondary antibodies. Antibody binding was detected using the ECL method. The analysed fractions were the cytosolic (lane 1) and
cytoskeleton fractions (lane 2), as well as anxA2 preparations derived from the cytoskeleton fraction by further puriﬁcation (lanes 3–5): 100000 · g
supernatant (lane 3), 100000 · g pellet (lane 4) and the DE52 ﬂow-through (lane 5). Selected prestained molecular mass markers are indicated.
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3B) or anxA2 (Fig. 3C) antibodies. Subsequent SDS–PAGE
and Western blot analysis with anxA2 (Fig. 3B) and Ub
(Fig. 3C) antibodies, respectively, demonstrated the presence
of several high-molecular-mass forms of Ub conjugates of
anxA2 (Ub-anxA2), in the range of 80–125 kDa (Figs. 3B
and 2C). Interestingly, these forms appeared as a ladder start-Fig. 3. Identiﬁcation of high-molecular-mass forms of annexin A2 as
ubiquitin conjugates. 30 lg of the anxA2 preparations puriﬁed from
porcine intestinal mucosa (in the presence of 600 mM KCl) (lanes 1
and 3) or mouse Krebs II cells (lanes 2 and 4) was subjected to (10%, w/
v) SDS–PAGE and Western blot analysis with monoclonal anxA2
antibodies before (A) and after (B) immunoisolation by Ub antibodies.
30 lg of the anxA2 preparations was likewise subjected to immuno-
isolation by anxA2 antibodies, subjected to 10% (w/v) SDS–PAGE and
Western blot analysis with monoclonal Ub antibodies (C). Primary
and secondary antibodies characterised by heavy and light chain IgG
subunits of 55 and 25 kDa, respectively, were recovered and
represent additional internal molecular mass markers (B, lane 5).
Antibody binding was detected using the ECL method and HRP-
conjugated goat anti-mouse secondary antibodies. Ub-anxA2 conju-
gates are indicated by a square bracket. Selected prestained molecular
mass markers are indicated.ing at 80 kDa, both when puriﬁed from porcine intestinal
mucosa and mouse Krebs II cells. This pattern was found to
be consistent in several preparations of puriﬁed anxA2. Bands
of 36 kDa are detected on the blot probed with anxA2 anti-
bodies (Fig. 3B), that most likely result from interaction of a
non-ubiquitinated form of anxA2 and a Ub-anxA2 species.
Note that the 50 kDa anxA2 positive band (Fig. 3A, lanes 1
and 2) is not immunoprecipitated under these conditions and
its nature remains to be identiﬁed. Interestingly, a 47 kDa
anxA2 form which is resistant to SDS-treatment, heat denatur-
ation and 2-mercaptoethanol reduction has previously been
reported [19].
3.4. Functional signiﬁcance of anxA2 ubiquitination
Since anxA2 contains an a-helical overall structure, we
searched for Ub-binding domains of a-helical secondary struc-
ture such as coupling of Ub conjugation to ER degradation
(CUE), Ub-associated (UBA) and Ub-interacting motif
(UIM) domains. The region 176GRRAEDGSVID (key resi-
dues underlined) spanning the ﬁfth helix of domain II appears
to contain a conserved UIM with Gly176 as a weak hydropho-
bic residue [20]. UIM-containing proteins both bind polyUb-
chains and promote ubiquitination [20]. Interestingly, UIM-
dependent polyubiquitination does not lead to degradation
of the modiﬁed protein. No UBA and CUE domains [21] were
found and the ubiquitination site(s) in anxA2 remains to be
identiﬁed. It should also be noted that anxA2 contains a spe-
cies conserved sequence 36RDALNIETA analogous to the
so-called ‘‘destruction box’’ linked to intracellular proteolysis
[22].
After having shown that anxA2 in vivo is a target protein
for ubiquitination, the question was whether this post-trans-
lational modiﬁcation represents a targeting signal for degra-
dation by the Ub-proteasome system. To address this
possibility, [35S] methionine labelled anxA2 was synthesised
in a coupled in vitro transcription/translation system, and
the stability of newly synthesised protein was followed by
206 S.U. Lauvrak et al. / FEBS Letters 579 (2005) 203–206further incubation in an enriched rabbit reticulocyte lysate
system as described [23]. However, neither ubiquitination
nor degradation of anxA2 during a 3-h chase was observed
(data not shown), presumably due to the lack of a substrate
speciﬁc Ub ligase or necessary ancillary proteins and/or
other post-translational modiﬁcations in this assay system.
Judged by the consistent pattern of anxA2-Ub conjugates
in the cellular extracts, it is concluded that polyUb forms
of anxA2 are relatively stable. Interestingly, it has been
found that the turnover of cytoskeleton-bound anxA2 in
the Triton-X 100 insoluble fraction (t1/2 = 40–50 h) in hu-
man lungs [14] is three to four times slower than for the sol-
uble anxA2 (t1/2 = 15 h). Thus, while degradation by
proteasomes is a process requiring a polyUb-chain with a
minimum of four Ub molecules in the chain linked in a
Lys48 branching conﬁguration [24], other Lys residues
in Ub have been reported to support the formation of
polyUb-chains, branching at Lys29 and Lys63 [25,26]. Ub-
chains in these conﬁgurations target the protein to non-pro-
teasome-dependent cellular processes such as DNA repair,
regulation of gene expression, apoptosis, and subnuclear
traﬃcking [26]. AnxA2 is involved in endocytosis [1] and
ubiquitination, in particular monoubiquitination, has also
been implicated in the internalisation of several plasma
membrane proteins destined to the endosomal/lysosomal
pathway [26].
The cellular functions of Ub are truly ubiquitous, since ubiq-
uitination regulates protein localisation, activity and binding
partners by a number of diﬀerent methods [26]. The ﬁnding
of an enrichment of polyUb anxA2 in the cytoskeleton fraction
suggests a function in a non-proteasomal process. AnxA2 is an
actin-binding protein and is associated with lipid rafts [1,3].
Considering that the Triton X-100 insoluble fraction contains
both cytoskeletal elements and certain lipids associated with
rafts and caveolae, it is possible that polyubiquitination may
be involved in the dynamic regulation of the actin cortical
cytoskeleton network as shown for some established regula-
tory proteins. Thus, the identiﬁcation in Saccharomyces cerevi-
siae of actin (Act1p) and some of its regulators (Rho3p, Sac6p,
and Rvs167p) as membrane-associated substrates for ubiquiti-
nation suggests a role of Ub as a direct regulator of the actin
cytoskeleton [27]. The possibility should therefore be consid-
ered that the binding of anxA2 to the actin cytoskeleton makes
it a substrate for speciﬁc Ub ligases associated with the cyto-
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